Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation (PERISCOPE) - Related Studies

Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation (PERISCOPE)

This study has been completed.

Study NCT00225277. Last updated on May 9, 2008. Information provided by Takeda Global Research & Development Center, Inc.

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Diabetes Mellitus, Type 2
		Coronary Artery Disease

2	Additional conditions recognized in this trial
		Diabetes Mellitus

3	More general conditions related to this trial
		Arterial Occlusive Diseases
		Arteriosclerosis
		Cardiovascular Diseases
		Coronary Disease
		Endocrine System Diseases
		Glucose Metabolism Disorders
		Heart Diseases
		Metabolic Diseases
		Myocardial Ischemia
		Vascular Diseases

4	Interventions listed in this trial
		pioglitazone HCl
		glimepiride

5	Additional drug interventions recognized in this trial
		Pioglitazone

6	More general drug interventions related to this trial
		Anti-Arrhythmia Agents
		Cardiovascular Agents
		Hypoglycemic Agents
		Immunologic Factors
		Immunosuppressive Agents
		Pharmacologic Actions
		Physiological Effects of Drugs
		Therapeutic Uses

7	Sponsors listed in this trial
		Takeda Global Research &Development Center, Inc.
		The Cleveland Clinic